PITTSBORO, NC--(Marketwire - October 12, 2007) - Biolex Therapeutics today announced that the results from its SELECT-1 Phase 2a clinical trial of Locteron™ have been selected for presentation at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston on November 6, 2007. Biolex also announced preliminary top-line results from the Phase 2a trial, a twelve-week study designed to evaluate a range of four doses of Locteron administered once every two weeks in combination with the antiviral drug ribavirin. In each of the two highest dose cohorts of the trial, the combination of Locteron and ribavirin resulted in an early virologic response (EVR) in 100% (16/16) of the hepatitis C patients treated. Importantly, the study results also suggested that patients receiving Locteron experienced side effects that were less frequent and less severe than those previously reported in clinical trials for the currently marketed pegylated interferons and for Albuferon™, a product candidate currently under development. Biolex is co-developing Locteron with its partner OctoPlus N.V.
